@article{d129d796a71244e0bb90eec9e4c5cb7c,
title = "Acalabrutinib: Managing adverse events and improving adherence in patients with mantle cell lymphoma",
abstract = "BACKGROUND: Acalabrutinib is a selective Bruton tyrosine kinase inhibitor approved for patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell malignancy. Treatment-related adverse events (AEs) can have a negative effect on treatment adherence. OBJECTIVES: This article aims to provide nurses with firsthand guidance so that they can better support patients with mantle cell lymphoma initiating acalabrutinib. METHODS: Safety data from the acalabrutinib ACE-LY-004 phase 2 trial in 124 patients with relapsed or refractory mantle cell lymphoma were reviewed, and strategies implemented at the University of Texas MD Anderson Cancer Center to manage trial AEs are described. FINDINGS: The most common AEs of any grade were headache and diarrhea, but no patients discontinued treatment because of them. When doses were missed or modified, patients were reeducated about the importance of adherence and how to manage AEs. Grade 1–2 AEs were managed with over-the-counter medication, if needed. These strategies allowed for the tracking of occurrences of nonadherence, providing the opportunity to advise and educate patients and to manage AEs more effectively.",
keywords = "Adherence, Adverse event, Bruton tyrosine kinase, Mantle cell lymphoma",
author = "Maria Badillo and Diana Nava and Rosa, {Maria Dela} and Wendy Chen and Maria Guerrero and Michael Wang",
note = "Funding Information: The authors take full responsibility for this content. The study was sponsored by Acerta Pharma, a member of the AstraZeneca Group. Medical writing support was provided by Adele Buss, PhD, of Oxford PharmaGenesis, Oxford, UK, funded by AstraZeneca LP. Badillo serves on the advisory board for and has received speaker honoraria from AstraZeneca. Wang has received grants from the University of Texas MD Anderson Cancer Center; personal fees and other from MORE Health; grants, personal fees, and nonfinancial support from Pharmacyclics; grants, personal fees, and nonfinancial support from Celgene; grants, personal fees, and nonfinancial support from Janssen; grants and personal fees from AstraZeneca/Acerta Pharma; Funding Information: personal fees and nonfinancial support from OMI; personal fees from Pulse Biosciences; grants from Novartis; grants from Juno; grants and personal fees from Loxo Oncology; grants from VelosBio; grants from BioInvent; personal fees from Targeted Oncology; grants and personal fees from Kite Pharma; and personal fees from Guidepoint Global. The article has been reviewed by independent peer reviewers to ensure that it is objective and free from bias. Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Oncology Nursing Society. Publisher Copyright: {\textcopyright} 2020, Oncology Nursing Society. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = aug,
doi = "10.1188/20.CJON.392-398",
language = "English (US)",
volume = "24",
pages = "392--398",
journal = "Clinical Journal of Oncology Nursing",
issn = "1092-1095",
publisher = "Oncology Nursing Society",
number = "4",
}